McNeil
AI Takes Leap Forward: ScreenPoint’s Transpara Boosts Early Detecttion of Breast Cancer
**New FDA-Cleared Capabilities Enable Earlier Detection of Density, Temporal Comparison
CHICAGO**, December 3, 2024 – At the Association for Radiology (RSNA)
Annual Meeting , Screenpoint Medical is showcasing groundbreaking new capabilities for Transpara, its industry-leading breast cancer artificial intelligence. These advancements, with FDA clearance, leverage additional training and insights from global users, furthering Transpara’s commitment to improving radiologists’ performance and enabling
Early Detection Through Innovation:
Transpara 2.1, the latest iteration of this AI system, integrates key features crucial for enhanced breast cancer detection. First, it introduces support for breast density assessments using both BIRADS and volumetric measures. This addition helps radiologists make more informed assessments in a key factor influencing breast cancer risk and diagnosis.
What sets Transpara 2.1 apart is its innovative temporal comparison capability.
This powerful feature allows for comparison of suspect areas from a current mammography study against up to three previous studies over a six-year span. Introducing this temporal analysis to the field, Transpara 2.1 empowers radiologists to track changes and better understand the long-term context of potential abnormalities.
“Taking tissue changes into consideration for characterizing findings is a long-awaited feature in AI development for breast cancer screening,” explains Professor Nico Karssemeijer, Co-founder and Chief Scientific Officer of ScreenPoint Medical. He emphasizes that, “We are truly excited about Transpara’s significant
performance improvement when utilizing a priori values, particularly when incorporating more of these values with extended time intervals—effectively mirroring radiologists’ experience.”
The new version minimally increases calculation time, striking a balance between streamlined workflow and in-depth analysis.
Impact Foundational in Reducing Diagnostic Delay:
ScreenPoint Medical’s commitment to evidence-based research is further solidified by
the results presented this week at RSNA.
Several presentations highlight the impact of Transpara in streamlining breast cancer screening on a large scale.
These studies demonstrate the power of Transpara 2.1 in several key areas:
-
Reducing Screening Turnaround Time: Research by UMass Memorial Health in a study titled "Putting It In Perspective: AI Triage Streamlining Screening Mammogram Turnaround Time (TAT) Amid Staff Shortages," decoded the effect AI software can have on optimizing the breast cancer screening process. Leveraging the Transpara score for prioritizing image review helped decrease the time it takes for radiologists to assess cases, proving beneficial for both efficiency and workload management.
- Enhanced Detection:
Further demonstrating its effectiveness,
research from the German breast cancer screening program showed.
https://www.screenpoint-medical.com/published-evidence/peer-reviewed-publications — for ```Transpara
**Proof Points, Confirmed by Research:**As a testament to its efficacy, Transpara has undergone rigorous research and validation with over 35 peer-reviewed publications,
unisex
forthcoming.
With multiple clinical trials, Vibrics published in real-world screening populations
across meglio, the
University of Lund in Sweden, and the Reina Sofía Hospital in Córdoba
Its ability to accurately detect
interval cancers, as demonstrated in various real-world scenarios.
biotechnology
Future of Breast Cancer Screening:
Transpara stands as the epitome of innovation,
translating cutting-edge machine learning into a readily accessible tool for radiologists worldwide.
Dedicated to
scre PartialEq
Acacia patrons should I see more information about the research presented by ScreenPoint Medical at the RSNA Annual Meeting?
## Interview with McNeil on AI Advancements in Breast Cancer Detection
**Host:** Welcome back to the show. Today we’re discussing some exciting news in the field of breast cancer detection. Joining us is McNeil, an expert in [McNeil’s Field – please specify], to break down these latest developments. McNeil, thank you for being here.
**McNeil:** Thanks for having me.
**Host:** Let’s dive right in. We’ve seen headlines about a new AI system called Transpara 2.1 and its potential to revolutionize early detection. Can you tell us more about it?
**McNeil:** Absolutely. Transpara 2.1, developed by ScreenPoint Medical, represents a significant leap forward in using AI for breast cancer screening. This new version boasts two key features: enhanced breast density assessment and groundbreaking temporal comparison capabilities.
**Host:** That sounds promising. Can you elaborate on what these features mean for patients and radiologists?
**McNeil:** Sure. First, the ability to assess breast density using both BIRADS and volumetric measures helps radiologists gain a more comprehensive understanding of a patient’s risk profile.
Secondly, the temporal comparison feature allows doctors to compare a current mammogram with up to three previous studies over a six-year period. This ability to track changes over time is truly groundbreaking and can help identify subtle abnormalities that might otherwise be missed.
[1]
**Host:** This sounds like a powerful tool. Are there any studies or evidence to support the efficacy of this new technology?
**McNeil:** Indeed, ScreenPoint Medical presented research at the recent RSNA Annual Meeting demonstrating the significant impact of Transpara in streamlining breast cancer screening. Their evidence-based approach is truly commendable.
**Host:** Fantastic. This is certainly encouraging news for anyone concerned about breast cancer. McNeil, thank you so much for sharing your insights with us.
**McNeil:** My pleasure. Remember, early detection remains crucial in the fight against breast cancer, and advancements like Transpara are offering renewed hope.
